curaleaf inc shares surrendered recent gains on tuesday after the usbased cannabis company missed analyst expectations reported a wider quarterly loss and said it expects 2021 revenue at the lower end of its estimated range curaleaf cura curlf said its thirdquarter net loss for the three months ending sept 30 widened to 564 million or 8 cents a share from 934 million or a penny a share in the year ago period revenue rose 74 to 31713 million to set a record revenue also gained 2 over the prior quarter’s tally of 31221 million thirdquarter operating expenses increased to 14275 million from 994 million in the yearago period curaleaf fell short of the analyst forecast for breakeven earnings and revenue of 3313 million according to a factset survey shares of curaleaf fell 5 giving back gains made on monday amid optimism around ma and potential moves on federal legalization of cannabis in congress looking ahead curaleaf executive chairman boris jordan said the company expects fullyear revenue to come in at the lower end of its prior guidance of 12 billion to 13 billion  “strategic ma remains a key pillar our growth plan” he said a day after the company announced plans to pay about 286 million to acquire privately held tryke companies to boost its presence in the southwestern us tim seymour who manages the amplify seymour cannabis etf cnbs  said he’s interested in adding to his position in curaleaf given the stock’s lower price on tuesday “i’d be a net buyer into curaleaf weakness today” he said “i give curaleaf credit for being the really the only multistate operator on some level that successfully navigated the national grid approach of deciding they wanted to be across the country curaleaf has made it to the other side and is the largest player in terms of the top line revenue” alliance global partners analyst aaron grey reiterated a buy rating on curaleaf on tuesday but lowered his price target to c23 a share from c29 a share “the company noted softness in northeast markets impacting the quarter” grey said in a research note “while we see nearterm softness as a function of specific market dynamics and oscillating maturity curves we also believe 2022 could see softer growth than we had previously modeled amid maturing markets and delays in adultuse sales beginning” on the plus side grey sees curaleaf’s research and development as well as its geographic presence both in the us and abroad as “positioning the company for longterm profitable growth despite various federal outcomes” he said meanwhile cowen analyst vivien azer late monday reiterated her outperform rating on curaleaf and said its sequential revenue growth beat her forecast “in terms of statespecific callouts we would note the emphasis on florida where the company has been criticized by some for promotional discounting” azer said in a research note “however this looks to be working in cura’s favor as the company’s instate profitability is above the corporate average over 30 adjusted ebitda while also having allowed the company to nearly double its market share yeartodate curaleaf shares are down 196 so far this year compared with a rise of 2 by the cannabis growth etf thcx  see also can industrial hemp become a sustainable building material these private investors think so